Amondys 45
Customize your policy alerts
Sign up for Cigna Policy IP0137 alerts
Get alerted when Policy IP0137 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical necessity for Amondys 45 (casimersen intravenous infusion) for patients with Duchenne muscular dystrophy. It applies to providers requesting prescription benefit coverage and requires specified clinical documentation, specialist involvement, and dosing.
Initial-therapy criteria now require that the patient has not received Elevidys.
The walking requirement was revised from a minimum independent 6-minute walk distance to ability to walk with submission of baseline 6-minute walk test results.
The forced vital capacity requirement was removed from the initial-therapy criteria.
Continuation therapy criteria were revised to require confirmation of an exon-45-skipping-amenable DMD mutation, age younger than 14 years at therapy initiation, and current ability to walk.
Concurrent use with other exon-skipping DMD therapies is explicitly identified as not medically necessary.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.